EMERGENT BIOSOLUTIONS INC. Proceeds from Convertible Debt
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2017-02-28
- EMERGENT BIOSOLUTIONS INC. proceeds from convertible debt for the quarter ending 2016-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from convertible debt for the quarter ending 2015-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from convertible debt for the quarter ending 2015-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from convertible debt for the quarter ending 2015-06-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from convertible debt for fiscal 2016 was $0.00.
- EMERGENT BIOSOLUTIONS INC. proceeds from convertible debt for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- EMERGENT BIOSOLUTIONS INC. proceeds from convertible debt for fiscal 2014 was $241.59M.
- EMERGENT BIOSOLUTIONS INC. proceeds from convertible debt for fiscal 2013 was $0.00.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 | ||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 derived: sum of 3 quarters · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | -$66.00K derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | -$66.00K derived: sum of 3 quarters · filed 2017-02-28 | -$66.00K derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | -$66.00K derived: sum of 2 quarters · filed 2017-02-28 | -$66.00K derived: sum of 3 quarters · filed 2017-02-28 | -$66.00K derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | -$66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$66.00K derived: sum of 2 quarters · filed 2017-02-28 | -$66.00K derived: sum of 3 quarters · filed 2017-02-28 | $241.59M 10-K · filed 2017-02-28 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $0.00 derived: sum of 2 quarters · filed 2015-11-06 | $241.65M 10-Q · filed 2015-11-06 | $241.65M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $241.65M 10-Q · filed 2015-08-06 | $241.65M derived: sum of 3 quarters · filed 2016-02-29 | $241.65M derived: sum of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | $241.65M 10-Q · filed 2015-05-08 | $241.65M derived: sum of 2 quarters · filed 2016-02-29 | $241.65M derived: sum of 3 quarters · filed 2016-02-29 | $241.65M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $0.00 derived: sum of 3 quarters · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $0.00 derived: sum of 2 quarters · filed 2014-11-10 | $0.00 10-Q · filed 2014-11-10 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $0.00 10-Q · filed 2014-08-08 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |